You feel the afternoon crash, the flat workouts, the drive that used to be automatic. A basic panel came back 'low normal' with a shrug. The real question is not just 'do something or nothing,' but how a careful provider decides which path fits when you may want children in the next few years.
The false binary: therapy now or nothing at all
Many people arrive assuming the only options are starting testosterone or ignoring symptoms entirely. That framing skips the most important variable: what your goals are, and what stays reversible.
The reason this matters for a fertility-minded man is mechanical. Exogenous testosterone (the standard injections or gels) can suppress the brain's signal to the testes. When the hypothalamic-pituitary-gonadal (HPG) axis senses enough circulating testosterone, it lowers luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and FSH is central to sperm production. Endocrine Society and urology guidance both note that exogenous testosterone can suppress spermatogenesis and is not appropriate for men who wish to preserve fertility [1][2].
Enclomiphene sits in a different category. It is an estrogen receptor modulator that blocks estrogen feedback at the hypothalamus, which tends to raise the body's own LH and FSH and, in turn, its own testosterone, rather than replacing it from outside [3]. That is the fertility-relevant distinction, and it is why 'do nothing yet' and 'consider enclomiphene' can both be reasonable, monitored paths for the same person.
What 'low normal' actually means
A single number rarely tells the story. The Endocrine Society recommends diagnosing low testosterone only with symptoms plus unequivocally low testosterone confirmed on repeat morning measurements, because testosterone follows a daily rhythm and varies between blood draws [1]. A one-off afternoon draw at urgent care is a weak basis for any decision, in either direction.
A thoughtful workup typically looks beyond total testosterone to LH, FSH, and sometimes free testosterone, estradiol, and prolactin. Those values help a provider distinguish a primary testicular issue from a signaling issue higher up the axis, which changes what 'wait and see' even means.
The 'wait and see' path, done deliberately
Doing nothing and monitoring deliberately are not the same thing. A structured watchful-waiting path usually pairs repeat labs with the levers that move the axis without a prescription.
Sleep, body composition, and alcohol all interact with testosterone. Short sleep has been shown to reduce daytime testosterone in healthy young men, which is directly relevant to a founder running on fumes [4]. Excess adipose tissue increases aromatization of testosterone to estradiol, and weight change is associated with measurable shifts in testosterone [5]. None of this is a promise; it is why a provider may reasonably ask for a monitoring window before recommending any medication.
Monitoring-first is also a fertility-protective default, because it commits to nothing that suppresses the HPG axis. If symptoms and labs both stay borderline, continuing to watch is a legitimate clinical choice, not a failure to act.
Source: [1] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
What would justify moving from monitoring to treatment
Providers generally look for a pattern, not a single trigger. Persistent, bothersome symptoms that are affecting function, paired with repeat morning labs that are consistently low rather than borderline, are the usual signals that the balance is shifting. Guidelines emphasize confirming low values on more than one occasion before treating [1].
For someone who wants to preserve fertility, the class of medication also matters at the decision point. This is where enclomiphene enters the conversation specifically because it aims to raise the body's own production rather than replace it, keeping LH and FSH signaling in play [3]. A provider weighs symptom burden, lab trajectory, fertility timeline, and personal risk factors together.
What stays reversible
Reversibility is one of the most useful lenses here. Because enclomiphene works by modulating feedback rather than supplying hormone from outside, its effect on the axis is generally not the same one-way suppression associated with exogenous testosterone [3]. If it is started and later stopped under provider guidance, the underlying signaling is not being replaced in the interim.
That does not make it consequence-free. Estrogen receptor modulators in this family carry known considerations, including visual disturbances and mood effects reported in the broader clomiphene literature, and any hormone-active medication warrants monitoring [2][3]. Reversibility is a reason to take the decision seriously, not lightly.
For readers navigating early or surgical menopause
The same principle, matching the intervention to the goal and monitoring over time, applies well beyond male fertility. After a hysterectomy, especially with early or surgical menopause, symptoms like night sweats, joint aches, and cognitive fog deserve a plan, not a handoff. Major medical societies support individualized hormone strategies for surgical and early menopause, with the specifics depending on whether the ovaries were removed and on personal risk factors [6]. The lesson that carries across both situations is continuity: a provider who revisits labs and symptoms over time, rather than one moment of decision.
A note on compounded options
Some hormone-related medications are available in compounded forms. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Whether any medication, compounded or otherwise, is appropriate is a decision only an independent licensed provider can make.
Where Velri fits
Velri is a technology and coordination company, not a medical provider. Velri helps coordinate the pieces of this decision so you are not assembling them alone: lab work to establish a real baseline (including repeat morning testosterone, LH, and FSH where indicated), a visit with an independent, physician-led Provider Group that can interpret those results in the context of your fertility goals, and, if an independent provider determines a prescription is appropriate, coordination with an independent licensed pharmacy. Coverage starts in Nevada, with more states rolling out over time.
A prescription is never guaranteed; whether to monitor, adjust lifestyle inputs, or consider a medication is decided entirely by an independent licensed provider through the Velri clinical review process. This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication.
